Neoplasia/BPH

	Comparison of Volumetric Modulated Arc Therapy and Fixed-Field Intensity-Modulated Radiotherapy for Canine Prostatic Carcinoma Using a 4.3â€‰Gyâ€‰Ã—â€‰10-Fraction Protocol: A Dosimetric Planning Study. Vet Comp Oncol Kim M, Jeong I, Eom K, Kim J. PMID: 42037153 [PubMed - as supplied by publisher]
	Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol Xu W, Rini BI, Albiges L, Tang X, Koeppen H, Bex A, Suárez C, Uzzo R, Master V, Karam JA, Hamidi H, Assaf ZJ, Dubey S, Goluboff ET, Carter C, Banchereau R, Huseni MA, Pal SK. PMID: 42036258 [PubMed - as supplied by publisher]
	Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivationâ€¯+â€¯enzalutamideâ€¯Â±â€¯zoledronic acid (BonEnza study). Bone Caramella I, Dalla Volta A, Valcamonico F, Bergamini M, Buffoni M, Zivi A, Procopio G, Sepe P, Di Meo N, Foti S, Zamboni S, Messina C, Rizzi A, Lucchini E, Ravanelli M, Zamparini M, Zacchi F, Laganà M, Cosentini D, Bresciani R, Suardi N, Farina D, Berruti A. PMID: 42035902 [PubMed - as supplied by publisher]
	Investigation of angiogenesis and epithelial-mesenchymal transition markers (CD31, VEGF, and E-Cadherin) in prostatic cancer patients: a multi-omics study. World J Surg Oncol Shahshenas S, Jalali Nadoushan M, Yarmohammadi H, Soltanipur M. PMID: 42035163 [PubMed - as supplied by publisher]
	Integrating multimodal clinical data with a large model for prostate cancer diagnosis. NPJ Digit Med Wang C, Tian Y, Yin S, Zhang X, Wei X, Wu L, Zhou Z, Pang G, Wang Y, Wu W, Zhao S, Wang Z, Xu J, He H, Li M, Jia Z, Gao X, Wang F, Zhai G, Xu B. PMID: 42034911 [PubMed - as supplied by publisher]
	Impact of spinal versus general anesthesia on dwell time of early immediate intravesical epirubicin administration following transurethral resection of bladder tumor: an observational study. World J Urol Kacan T, Tezcan B, Yildiz AK, Gokkurt Y, Demir DO, Erbay OF, Keseroglu BB, Karakan T. PMID: 42034706 [PubMed - in process]
	Re: Fecal Microbiota Transplantation plus Pembrolizumab and Axitinib in Metastatic Renal Cell Carcinoma: The Randomized Phase 2 TACITO Trial. Eur Urol Yao Y, Liu Y, Li Y, Lu B, Cui X, Pan X. PMID: 42034536 [PubMed - as supplied by publisher]
	Towards a better understanding of kidney CANCER: Genetically engineered mouse models and biomarkers insights. Biochim Biophys Acta Rev Cancer De Castro L, Claude O, Gad S, Guéguen Y. PMID: 42034324 [PubMed - as supplied by publisher]
	The Risk of Benign Prostatic Hyperplasia and Prostate Cancer With Long-Term, Low Dose Finasteride Use in Adult Men with Nonscarring Alopecia: A Propensity-Matched Observational Study. Urology Adler R, Kozlov M, Viola J, Ingram J, Jeune KR, Feig JL, Winer A, Weiss JP. PMID: 42034292 [PubMed - as supplied by publisher]
	Hypocholesterolemia is a consequence, not a cause, of kidney cancer: A bidirectional Mendelian randomization study with NHANES 2001-2018. Cancer Epidemiol Zhang X, Tu Z, Zhao M, Qiu W. PMID: 42033882 [PubMed - as supplied by publisher]
	An explainable clinical-radiomics machine learning model for preoperative prediction of WHO/ISUP nuclear grade in clear cell renal cell carcinoma. Abdom Radiol (NY) Li Y, Lin M, Sun L, Dong C, Yang J, Li X, Lin Y, Wu J, Zhao J, Lin C. PMID: 42033642 [PubMed - as supplied by publisher]
	Addressing the challenges of health economic modelling in the context of suboptimal evidence base - case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer. J Med Econ Belsey J, Chrosny W, Lapon J. PMID: 42033426 [PubMed - indexed for MEDLINE]
	Fatty Acid Intake and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran. Nutr Cancer Seyyedsalehi MS, Hadji M, Rashidian H, Naghibzadeh-Tahami A, Marzban M, Zendehdel K, Boffetta P. PMID: 42033127 [PubMed - as supplied by publisher]
	PRIMA: randomized prospective multicenter non-inferiority study for primary diagnosis of clinically significant PRostate cancer by PSA and MR IMAging-study protocol for a randomized diagnostic accuracy trial. Trials Al-Monajjed R, Albers P, Boschheidgen M, Radtke JP, Droop J, Benner A, Hadaschik B, Antoch G, Schimmöller L, PRIMA Study Group. PMID: 42032761 [PubMed - indexed for MEDLINE]
	Structured reporting of B-mode, color Doppler, and CEUS in testicular tumor assessment: a reader study with urologist ratings. BMC Urol Schnitzer ML, Biechele G, Eckermann C, Herr FL, Dascalescu C, Heimer M, Schwarze V, Marcon J, Lenhart M, Waldbillig F, Baier F, Clevert DA, Frölich MF, Rübenthaler J, Geyer T. PMID: 42032677 [PubMed - as supplied by publisher]
	Diagnostic performance of PSMA PET/CT and multiparametric MRI for local prostate cancer recurrence after high-intensity focused ultrasound. Curr Probl Diagn Radiol Saeed S, Sommer D, Phillipi M, Houshyar R. PMID: 42031651 [PubMed - as supplied by publisher]
	Re: Ipilimumab and Nivolumab Followed by Chemoradiotherapy as Bladder-sparing Treatment in Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol Lu W, Chen L. PMID: 42031581 [PubMed - as supplied by publisher]
	Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial. BMJ Open Loper M, Qadar A, Vesely SK, Gunter T, Ayanambakkam A, Wen Y, Cookson M, Stratton K. PMID: 42031503 [PubMed - indexed for MEDLINE]
	Aging is associated with the outcomes of immune checkpoint blockade in renal cell carcinoma. J Immunother Cancer Huang Z, Zhou J, Zheng Z, Zhao H, Zhao B, Zeng R. PMID: 42031430 [PubMed - indexed for MEDLINE]
	Phase 2 trial of pTVG-HP Â± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer Kyriakopoulos CE, Pachynski RK, Eickhoff JC, Tonelli TP, Jeon D, McNeel DG. PMID: 42031429 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 187317

Page 1 of 9366



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy